Evaluation of costs of epilepsy using an electronic practice management software in Germany

• Evaluation of 359 patients in 2011 with electronic practice management software.
• Annual direct costs amounted to €1698 per patient.
• Indirect costs due to absenteeism amounted to €745 per patient.
• Cost-driving factors were higher seizure frequency and a recent diagnosis of epilepsy.
• Electronic evaluations will facilitate large, prospective and multicentre clinical trials.

PurposeThis study used an electronic practice management software in daily routine to gather long-term disease and cost-of-illness (COI) data in patients with epilepsy in Germany.MethodsData on socio-economic status, course of epilepsy as well as direct and indirect costs were recorded using practice software-based questionnaires.ResultsIn 2011 we enrolled 359 patients (170 male (47.4%); mean age 50.5 ± 20.7 years) in six neurological practices. The majority of patients had been in long-term seizure remission for more than one year (n = 200, 55.7%) and in more than two-thirds the anti-epileptic drug (AED) monotherapy (n = 248, 69.1%) was used. Levetiracetam (31%), lamotrigine (26%) and valproate (24%) were the drugs prescribed most frequently.Total annual direct costs amounted to €1698 per patient with anticonvulsants (59.9% of total direct costs) and hospitalization (30.0%) as the main cost factors. Of the patients enrolled 252 (70.2%) were of working age and indirect annual costs due to absenteeism amounted to €745 per patient.Potential cost-driving factors were seizure frequency and a recent diagnosis of epilepsy associated with higher costs. Anticonvulsant treatment in patients aged 65 years and older was associated with lower drug costs due to prescription of older AEDs.ConclusionWe were able to demonstrate that electronic practice management software can easily be used to perform long-term health economic evaluations with a bottom-up approach. The combination of both physician- and patient-based electronic databases will facilitate performing less expensive studies, but at the same time simplify large, prospective and multicentre clinical trials.